

FLUOROQUINOLONES IN TREATMENT OF THE DIABETIC FOOT SYNDROME: PRO ET CONTRA

O.A. Galushko

Summary. The article is dedicated to study of the particularities of the fluoroquinolones use during treatment patients with diabetic foot syndrome (DFS). 38 patients at age 31–80 with pio-necrotic complications of DFS, which corresponded to IIIa-IVb stage for Wagner have divided into 2 groups. Patients of the first group had got gatifloxacin (Bigafon) in dose 400 mg/day. The Second (control) group has formed 20 patients, which had got ceftriaxon in complex therapy. The study has not revealed the reliable difference in frequency of the negative effects (hypoglycaemia, cardiac arrhythmia) and has demonstrated the improvement of the current of the defeats and stabilization laboratory-biochemical factors beside patients, which in program of the treatment got new fluoroquinolone Bigafon.

Key words: *fluoroquinolones, gatifloxacin, Bigafon, complications, hypoglycaemia, arrhythmia, diabetic foot syndrome.*